Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. - Wikidata - awgldk - TriplyDB

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

http://www.wikidata.org/entity/Q37990969

about

MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors.Robustness of signal transduction pathways.Targeting MAPK pathway in melanoma therapy.Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis.High-throughput sequencing of the melanoma genome.The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth.Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer

P2860

Q28118859-BC3E865D-5641-4963-9FBF-55513400E34F Q34615593-8D9901E2-8948-4F78-8152-E3FDCF507E9B Q36337063-BD1C3EFE-558B-4DC0-BE58-0E2964C0DB0C Q37060963-0F3DBFDD-5A94-4D3E-B020-E0FE00FEDFDA Q38046128-BBDCA323-AE00-45BD-B6DF-CE418382D14C Q38098888-2600EF20-FB38-43E1-BDBB-710874E49B3A Q38123513-13FC730B-3C86-4260-93AE-B472CA7AD1D5 Q39035993-8AB1A9E9-486F-4C8B-9511-0CAF091D9502 Q42773490-552C8F14-7387-40DF-8BF0-EC6E3431A4D0 Q49364393-35488B99-9E44-4EDB-921D-3790E98D237D Q57156789-5B8BAECC-7D46-4AC0-9F01-50D0994D7D08

P2860

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

http://www.wikidata.org/entity/Q37990969

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

@en

Selumetinib

@nl

type

label

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

@en

Selumetinib

@nl

prefLabel

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

@en

Selumetinib

@nl

P1433

Q37990969-545FD944-AD14-415E-AEFC-79D45CA7D367

P1476

Q37990969-81C67D50-B3F6-4CEA-A5CF-9B6BAF89BA5B

P2093

Q37990969-C3876E99-622E-4FEE-801F-9F4CE2E39259

Q37990969-EF8BDE23-133E-4458-AEAC-5F501A8F494E

P2860

Q37990969-178B47A8-0691-461F-9892-F4A6673D7140

Q37990969-18C4F5D5-1BCC-41D4-B271-AD1E573F24C3

Q37990969-1ABDA297-E0A1-436D-B246-7D61C9E4FF95

Q37990969-1C876057-0DED-48D5-8F84-BF0C5A28A2DF

Q37990969-1FA55BCE-D630-4D8E-80A8-856700236B06

Q37990969-26DAEF03-4BF9-4171-8C14-BD7DEF58325E

Q37990969-2712D099-A0EA-442F-9AC0-6803BB5EF4BD

Q37990969-279996B0-255F-4250-ADD9-7996CE878ACF

Q37990969-2923AA00-CE41-4FF8-884C-8A0D2285FE17

Q37990969-29471E21-8C49-4DD7-8680-069E041F9E90

P304

Q37990969-FEE17863-B299-46AE-9C34-2DEBB49BD8FA

P31

Q37990969-769BCB39-2F27-4BD5-9813-C00FC6C053E7

P356

Q37990969-3EE6D32F-EE3A-491B-9539-7E9D60B2C09E

P407

Q37990969-366099B3-D89B-4275-B28A-BCB1DE29ED7F

P433

Q37990969-6B190CC5-48A5-402C-A668-7CFB65D91AC3

P478

Q37990969-411ECCC5-6855-4F8E-A497-09561E948A8B

P577

Q37990969-4CFBDB75-1BA3-4762-9FE0-87EC442E08C9

P698

Q37990969-17CC5EF7-9D35-4A9C-B823-2CC0C3478B9C

P921

Q37990969-A0F979DE-7B2F-446E-84C9-489EBB2D8DB1

P356

13543784.2012.665871

P1433

Expert Opinion on Investigational Drugs

P1476

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

@en

P2093

Kevin B Kim

http://www.w3.org/2001/XMLSchema#string

Sapna P Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in GNA11 in uveal melanoma

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.

Mutations of the BRAF gene in human cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

P304

531-539

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2012.665871

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22394161

http://www.w3.org/2001/XMLSchema#string

P921